New study reveals how antibody levels shape Long COVID recovery

A new study from Okayama University has examined the link between antibody levels and Long COVID symptoms. The research involved 275 patients who were infected during the Omicron variant period. It highlights how certain antibodies may influence the persistence and severity of the condition. The study centred on two types of antibodies: spike (S) protein and nucleocapsid (N) protein. Researchers found that lower S-antibody levels were connected to memory problems in Long COVID sufferers. These levels also appeared to rise with the number of COVID-19 vaccine doses a person had received.

N-antibody levels showed different patterns. They were higher in female patients compared to males. These antibodies were also tied to immune factors like lymphocyte counts and immunoglobulin levels. Additionally, N-antibody concentrations reflected the initial severity of the infection and decreased by around 0.34% each day in unvaccinated individuals.

Higher S-antibody levels were linked to a better self-reported quality of life among patients. The findings suggest that measuring these antibodies could help identify those at greater risk of long-lasting symptoms. This may allow for more personalised treatment approaches. The study provides valuable insights into the role of antibodies in Long COVID. It shows that antibody levels can indicate symptom severity and recovery trends. These results may assist in developing targeted interventions for affected individuals.